Forskningsgruppe i samfunnsfarmasi


There has not been added a translated version of this content. You can either try searching or go to the "area" home page to see if you can find the information there

Patients with acute intermittent porphyria (AIP)

Porphyria is a collective term for a group of rare inherited or aquired diseases caused by enzyme disturbances in the heme-synthethising pathway.


Some drugs may cause an onset of AIP within the patients with this rare enzyme disorder. The symptoms are abdominal pain, vomiting, tachycardia, hypertension, muscleweakness and -pain, mental disturbances, paresis, and at worst - respiratory failure.

The group coopertaes with NAPOS (national centre for porphyria), to gain more knowledge about these objectives:

  • Which drugs can safely be used by patients with AIP, and which drugs may cause onset of symptoms?
  • How can we best deliver this information to both patients with AIP and the health care personell that are treating them?